Cargando…

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus

Intravenous (i.v.) temsirolimus, a novel inhibitor of mammalian target of rapamycin, is approved for the treatment of advanced renal cell carcinoma and is being studied in patients with mantle cell lymphoma. Because temsirolimus and its primary metabolite, sirolimus, are metabolised by the cytochrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, J P, Leister, C, Burns, J, Hug, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410110/
https://www.ncbi.nlm.nih.gov/pubmed/18458675
http://dx.doi.org/10.1038/sj.bjc.6604376